Potent Selectivity: Nimbus Entrusts IRAK4 Program To Genentech
This article was originally published in Scrip
Even the most ambitious early-stage biopharma has to prioritize which programs it will take on itself and which might advance more quickly and fully in the hands of a more-experienced and deeper-pocketed partner. Having used its computational chemistry platform to generate IRAK4 inhibitors with potential in autoimmune disease and B-cell lymphomas, Nimbus Therapeutics has licensed global rights to that program to Genentech Inc.
You may also be interested in...
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.